American Fusion Expands Texatron Patent Portfolio to 151 Applications, Advances Testing Infrastructure and National Exchange Uplisting Plans

American Fusion Inc. (OTCQB: AMFN), a company developing fusion energy technology, has announced significant progress in its intellectual property portfolio, testing infrastructure, and plans for a potential uplisting to a national securities exchange.

The company recently filed 21 new U.S. patent applications related to its Texatron™ fusion platform, expanding its total pending U.S. applications to 151. These filings cover a broad range of innovations including architectures, materials, geometries, components, and operating methods integral to the Texatron technology. American Fusion emphasized that all patent applications remain subject to examination by the United States Patent and Trademark Office (USPTO) and that there is no guarantee of issuance or the scope of any patents granted.

Alongside its intellectual property efforts, American Fusion continues testing activities at a university laboratory. Additionally, the company has identified a site for a dedicated, company-controlled testing facility and has negotiated principal terms and purchase price for the acquisition. However, the closing of this transaction remains contingent on customary conditions and is not yet finalized.

In parallel with technology development, American Fusion is positioning itself for a potential uplisting from the OTCQB marketplace to a national securities exchange. The company is favoring the Texas Stock Exchange (TXSE) but is also evaluating other major exchanges including the New York Stock Exchange (NYSE) and Nasdaq. Based on current assessments, American Fusion believes it meets all TXSE listing criteria except for the minimum bid price requirement, which may necessitate a reverse stock split.

The company has received several financing term sheets linked to both the uplisting process and funding for Texatron commercialization. However, no definitive financing agreements have been executed to date. American Fusion cautioned that any reverse stock split undertaken to meet minimum bid price rules could dilute existing shareholders’ interests.

As of June 30, 2026, American Fusion reported cash and cash equivalents of $79,341, which covers approximately 11.5 days of operating cash outflow based on the last quarter’s expenditure of $626,781. The company noted that its national exchange uplisting plans remain in a preparatory phase, with no venue selected and no binding financing agreements in place. Therefore, this corporate update does not commit to an uplisting or any new issuance that would alter current common shareholders’ ownership.

American Fusion outlined that the next steps include an additional Securities and Exchange Commission (SEC) filing related to the proposed testing facility transaction, execution of any definitive financing agreements, and completion of the selected exchange’s review and approval process.

The company’s strategic moves to expand its patent portfolio, secure dedicated testing infrastructure, and pursue a national exchange uplisting reflect its efforts to advance the commercialization of its Texatron fusion technology and enhance shareholder value through broader market access.